EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：9
|
作者：
Shivashankar, Raina
Ladd, Antonio H. Mendoza
Grace, Rory
Aberra, Faten
Lichtenstein, Gary R.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)30608-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
304
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [1] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
    Sierra Morales, M.
    Birdi, S.
    Samaan, M. A.
    Brown-Clarke, C.
    Duncan, J.
    Stanton, A.
    Koumoutsos, I.
    Anderson, S.
    Ray, S.
    Mawdsley, J.
    Sanderson, J.
    Irving, P. M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452
  • [2] VEDOLIZUMAB DOSE ESCALATION AS A WAY OF RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Birdi, S.
    Sierra Morales, M.
    Samaan, M. A.
    Brown-Clarke, C.
    Stanton, A.
    Ray, S.
    Koumoutsos, I.
    Mawdsley, J.
    Anderson, S.
    Sandersdon
    Irving, P. M.
    GUT, 2018, 67 : A69 - A70
  • [3] Predictors of Vedolizumab Dose Escalation or Cessation in Inflammatory Bowel Disease Patients
    Razvi, Mohammed A.
    Chowdhury, Reezwana
    Parian, Alyssa
    Melia, Joanna
    Truta, Brindusa
    Brant, Steve
    Dudley-Brown, Sharon
    Lazarev, Mark
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S417 - S418
  • [4] Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Yarur, Andres J.
    Graziano, Elliot
    Campbell, James P.
    Bhattacharya, Abhik
    Lee, Jennifer Y.
    Gheysens, Katherine
    Papamichael, Konstantinos
    Osterman, Mark T.
    Cheifetz, Adam S.
    Cross, Raymond K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
  • [5] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [6] OUTCOMES OF DOSE ESCALATION AND DRUG LEVEL MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB
    Scoville, Elizabeth A.
    Izmaylov, Michelle L.
    Bennett, Audrey
    Evers, Lauren
    Annis, Kim
    Garrett, Ailish
    Duley, Caroline
    Adams, Dawn W.
    Dalal, Robin L.
    Beaulieu, Dawn
    Schwartz, David A.
    Horst, Sara N.
    GASTROENTEROLOGY, 2018, 154 (06) : S829 - S830
  • [7] COSTS OF DOSE ESCALATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB AND USTEKINUMAB IN PORTUGAL
    Lopes da Cruz, J. P.
    Faria, M.
    Aleixo, A. S.
    Pereira, F.
    VALUE IN HEALTH, 2023, 26 (12) : S504 - S505
  • [8] Effect of Ustekinumab Dose Escalation on Recapturing Clinical Response in Patients With Crohn's Disease
    Bundschuh, Mark
    McDonough, Gregory
    Kumar, Priyanka
    Kozuch, Patricia
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S452 - S452
  • [9] Effect of obesity on vedolizumab response in inflammatory bowel disease
    Levine, Louis
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Viana, Artur V.
    Al-Bawardy, Badr
    ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
  • [10] EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Viana, Artur V.
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2021, 160 (06) : S703 - S704
12345